- Home
- ELEV vs BTAI Comparison
ELEV vs BTAI Comparison
Compare ELEV & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- BTAI
- Stock Information
- Founded
- ELEV 2019
- BTAI 2017
- Country
- ELEV United States
- BTAI United States
- Employees
- ELEV N/A
- BTAI N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- BTAI Health Care
- Exchange
- ELEV Nasdaq
- BTAI Nasdaq
- Market Cap
- ELEV 34.0M
- BTAI 28.7M
- IPO Year
- ELEV 2021
- BTAI 2018
- Fundamental
- Price
- ELEV $0.61
- BTAI $0.57
- Analyst Decision
- ELEV Strong Buy
- BTAI Strong Buy
- Analyst Count
- ELEV 5
- BTAI 4
- Target Price
- ELEV $7.80
- BTAI $5.00
- AVG Volume (30 Days)
- ELEV 673.9K
- BTAI 465.8K
- Earning Date
- ELEV 11-06-2024
- BTAI 11-14-2024
- Dividend Yield
- ELEV N/A
- BTAI N/A
- EPS Growth
- ELEV N/A
- BTAI N/A
- EPS
- ELEV N/A
- BTAI N/A
- Revenue
- ELEV N/A
- BTAI $2,276,000.00
- Revenue This Year
- ELEV N/A
- BTAI $247.03
- Revenue Next Year
- ELEV N/A
- BTAI $88.16
- P/E Ratio
- ELEV N/A
- BTAI N/A
- Revenue Growth
- ELEV N/A
- BTAI 83.25
- 52 Week Low
- ELEV $0.44
- BTAI $0.50
- 52 Week High
- ELEV $5.83
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- ELEV 51.53
- BTAI 44.39
- Support Level
- ELEV $0.52
- BTAI $0.51
- Resistance Level
- ELEV $0.70
- BTAI $0.61
- Average True Range (ATR)
- ELEV 0.06
- BTAI 0.07
- MACD
- ELEV 0.00
- BTAI -0.01
- Stochastic Oscillator
- ELEV 41.81
- BTAI 27.15
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.